Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
- 1 June 2005
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 27 (6) , 684-694
- https://doi.org/10.1016/j.clinthera.2005.06.003
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal AntibodiesJournal of Clinical Oncology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- The Hallmarks of CancerCell, 2000
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Humanized Antibodies as Potential Therapeutic DrugsAnnals of Allergy, Asthma & Immunology, 1998
- Inhibitors of tyrosine kinaseCurrent Opinion in Oncology, 1997
- Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal AntibodiesCancer Biotherapy, 1994
- Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal AntibodiesJNCI Journal of the National Cancer Institute, 1993
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975